LEAPS Vaccine Incorporating HER-2/neu Epitope Elicits Protection That Prevents and Limits Tumor Growth and Spread of Breast Cancer in a Mouse Model
The prototype J-LEAPS T cell vaccine for HER-2/neu breast cancer (J-HER) consists of the murine HER-2/neu66–74 H-2d CD8 T cell epitope covalently attached through a triglycine linker to the J-immune cell binding ligand (ICBL) (human β2 microglobulin38–50 peptide). The J-ICBL was chosen for its poten...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2017-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2017/3613505 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832551662912274432 |
|---|---|
| author | Ken S. Rosenthal Sarah Stone Gary Koski Daniel H. Zimmerman |
| author_facet | Ken S. Rosenthal Sarah Stone Gary Koski Daniel H. Zimmerman |
| author_sort | Ken S. Rosenthal |
| collection | DOAJ |
| description | The prototype J-LEAPS T cell vaccine for HER-2/neu breast cancer (J-HER) consists of the murine HER-2/neu66–74 H-2d CD8 T cell epitope covalently attached through a triglycine linker to the J-immune cell binding ligand (ICBL) (human β2 microglobulin38–50 peptide). The J-ICBL was chosen for its potential to promote Th1/Tc1 responses. In this proof-of-concept study, the ability of J-HER to prevent or treat cancer was tested in the TUBO cell-challenged BALB/c mouse model for HER-2/neu-expressing tumors. The J-HER vaccine was administered as an emulsion in Montanide ISA-51 without the need for a more potent adjuvant. When administered as a prophylactic vaccination before tumor challenge, J-HER protected against tumor development for at least 48 days. Despite eliciting protection, antibody production in J-HER-immunized, TUBO-challenged mice was less than that in unimmunized mice. More importantly, therapeutic administration of J-HER one week after challenge with TUBO breast cancer cells limited the spread of the tumors and the morbidity and the mortality in the challenged mice. The ability to elicit responses that prevent spread of the TUBO tumor by J-HER suggests its utility as a neoimmunoadjuvant therapy to surgery. Individual or mixtures of J-LEAPS vaccines can be readily prepared to include different CD8 T cell epitopes to optimize tumor therapy and customize treatment for individuals with different HLA types. |
| format | Article |
| id | doaj-art-3d37a31ef86b4931b9f4646381aef4ad |
| institution | Kabale University |
| issn | 2314-8861 2314-7156 |
| language | English |
| publishDate | 2017-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Immunology Research |
| spelling | doaj-art-3d37a31ef86b4931b9f4646381aef4ad2025-02-03T06:00:54ZengWileyJournal of Immunology Research2314-88612314-71562017-01-01201710.1155/2017/36135053613505LEAPS Vaccine Incorporating HER-2/neu Epitope Elicits Protection That Prevents and Limits Tumor Growth and Spread of Breast Cancer in a Mouse ModelKen S. Rosenthal0Sarah Stone1Gary Koski2Daniel H. Zimmerman3College of Medicine, Roseman University of Health Sciences, 10530 Discovery Drive, Las Vegas, NV 89135, USANortheast Ohio Medical University, Rootstown, OH 44272, USAKent State University, Kent, OH 44240, USACEL-SCI Corporation, 8229 Boone Blvd, Suite 802, Vienna, VA 22182, USAThe prototype J-LEAPS T cell vaccine for HER-2/neu breast cancer (J-HER) consists of the murine HER-2/neu66–74 H-2d CD8 T cell epitope covalently attached through a triglycine linker to the J-immune cell binding ligand (ICBL) (human β2 microglobulin38–50 peptide). The J-ICBL was chosen for its potential to promote Th1/Tc1 responses. In this proof-of-concept study, the ability of J-HER to prevent or treat cancer was tested in the TUBO cell-challenged BALB/c mouse model for HER-2/neu-expressing tumors. The J-HER vaccine was administered as an emulsion in Montanide ISA-51 without the need for a more potent adjuvant. When administered as a prophylactic vaccination before tumor challenge, J-HER protected against tumor development for at least 48 days. Despite eliciting protection, antibody production in J-HER-immunized, TUBO-challenged mice was less than that in unimmunized mice. More importantly, therapeutic administration of J-HER one week after challenge with TUBO breast cancer cells limited the spread of the tumors and the morbidity and the mortality in the challenged mice. The ability to elicit responses that prevent spread of the TUBO tumor by J-HER suggests its utility as a neoimmunoadjuvant therapy to surgery. Individual or mixtures of J-LEAPS vaccines can be readily prepared to include different CD8 T cell epitopes to optimize tumor therapy and customize treatment for individuals with different HLA types.http://dx.doi.org/10.1155/2017/3613505 |
| spellingShingle | Ken S. Rosenthal Sarah Stone Gary Koski Daniel H. Zimmerman LEAPS Vaccine Incorporating HER-2/neu Epitope Elicits Protection That Prevents and Limits Tumor Growth and Spread of Breast Cancer in a Mouse Model Journal of Immunology Research |
| title | LEAPS Vaccine Incorporating HER-2/neu Epitope Elicits Protection That Prevents and Limits Tumor Growth and Spread of Breast Cancer in a Mouse Model |
| title_full | LEAPS Vaccine Incorporating HER-2/neu Epitope Elicits Protection That Prevents and Limits Tumor Growth and Spread of Breast Cancer in a Mouse Model |
| title_fullStr | LEAPS Vaccine Incorporating HER-2/neu Epitope Elicits Protection That Prevents and Limits Tumor Growth and Spread of Breast Cancer in a Mouse Model |
| title_full_unstemmed | LEAPS Vaccine Incorporating HER-2/neu Epitope Elicits Protection That Prevents and Limits Tumor Growth and Spread of Breast Cancer in a Mouse Model |
| title_short | LEAPS Vaccine Incorporating HER-2/neu Epitope Elicits Protection That Prevents and Limits Tumor Growth and Spread of Breast Cancer in a Mouse Model |
| title_sort | leaps vaccine incorporating her 2 neu epitope elicits protection that prevents and limits tumor growth and spread of breast cancer in a mouse model |
| url | http://dx.doi.org/10.1155/2017/3613505 |
| work_keys_str_mv | AT kensrosenthal leapsvaccineincorporatingher2neuepitopeelicitsprotectionthatpreventsandlimitstumorgrowthandspreadofbreastcancerinamousemodel AT sarahstone leapsvaccineincorporatingher2neuepitopeelicitsprotectionthatpreventsandlimitstumorgrowthandspreadofbreastcancerinamousemodel AT garykoski leapsvaccineincorporatingher2neuepitopeelicitsprotectionthatpreventsandlimitstumorgrowthandspreadofbreastcancerinamousemodel AT danielhzimmerman leapsvaccineincorporatingher2neuepitopeelicitsprotectionthatpreventsandlimitstumorgrowthandspreadofbreastcancerinamousemodel |